Excess mortality related to cefepime

The Lancet Infectious Diseases

Volumn 10, Issue 5, 2010, Pages 293-294

  Leibovici, Leonard ^a,b   Yahav, Dafna ^a,b   Paul, Mical ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYING; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; BACTERIAL INFECTION; METHODOLOGY; POSTMARKETING SURVEILLANCE; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; HUMANS; MORTALITY; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77951887854     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70070-0     Document Type: Letter

References (4)

1. Clinical review of cefepime 2009, FDA, US Food and Drug Administration, Silver Spring, MD, (accessed Jan 21, 2010). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM167313.pdf.
2. Paul M, Yahav D, Fraser A, Leibovici L Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006, 57:176-189.
3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007, 7:338-348.
4. NDA 50-679, cefepime hydrochloride, statistical evaluation of mortality risk 2009, FDA, US Food and Drug Administration, Silver Spring, MD, (accessed Jan 21, 2010). http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM167309.pdf.